More articles about Astrazeneca | Wall St. Cheat Sheet

April 23, 2013

Astrazeneca Earnings Preview: Can This Streak Continue?

Here's your Cheat Sheet to earnings...

April 05, 2013

Can This Business Help Pfizer in Emerging Markets?

Pfizer will not be divesting its $3.2 billion-a-year consumer health unit...

April 03, 2013

AstraZeneca Gets Patent Blow and 4 Stocks At 52-Week Highs

See which companies are seeing their stock prices at annual highs right now...

April 02, 2013

HP’s Downgrade, Healthcare’s Upgrade, and Strong Auto Sales: Market Recap

The U.S. equity markets advanced on Tuesday. Investors seem to brush aside poor manufacturing data out of Europe and took strong U.S. factory orders data as a good omen. The Dow and S&P set fresh records...

April 02, 2013

Here’s A Blow To AstraZeneca’s Drug Portfolio

A United States District Court in New Jersey ruled Tuesday that the patent protecting the company’s asthma drug is invalid...

January 31, 2013

Has AstraZeneca Fallen Off the Patent Cliff?

The patent cliff -- the expiration of patents on blockbuster pharmaceuticals -- cost drug manufacturers $36 billion in 2012 and will decrease sales by an estimated $25 billion this year...

January 15, 2013

How Will AstraZeneca Fare With These Losses?

Britain's second largest pharmaceutical company, AstraZeneca, will face its second large shake-up in two months, with the exit of two top officials from the company...

December 06, 2012

Pharmaceuticals: EU Courts Lay Down the Law

The pharmaceutical industry was dealt a heavy blow Thursday as AstraZeneca's 52.5-million-euro fine for breaking antitrust laws is upheld in the EU's highest court...

October 07, 2012

AstraZeneca’s New Strategy

Pharmaceutical manufacturer AstraZeneca announced Monday that it would suspend share buybacks as the board and new Chief Executive Officer Pascal Soriot review the company’s strategy...